CA Patent

CA2688467C — Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Assigned to Wyeth LLC · Expires 2015-05-12 · 11y expired

What this patent protects

The present invention provides 4-aminoquinoline 3-carbonitirle compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.

USPTO Abstract

The present invention provides 4-aminoquinoline 3-carbonitirle compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib.

Drugs covered by this patent

bosutinib-monohydrate (BOSUTINIB MONOHYDRATE)

Patent Metadata

Patent number: CA2688467C
Jurisdiction: CA
Classification: —
Expires: 2015-05-12
Drug substance claim: No
Drug product claim: No
Assignee: Wyeth LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.